Enhanced Immunogenicity and Protective Efficacy of a <italic toggle="yes">Campylobacter jejuni</italic> Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21
ABSTRACT Campylobacter jejuni is among the most common causes of diarrheal disease worldwide and efforts to develop protective measures against the pathogen are ongoing. One of the few defined virulence factors targeted for vaccine development is the capsule polysaccharide (CPS). We have developed a...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
American Society for Microbiology
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e799a4b22d0c4f43842f64674b689c7b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e799a4b22d0c4f43842f64674b689c7b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e799a4b22d0c4f43842f64674b689c7b2021-11-15T15:22:20ZEnhanced Immunogenicity and Protective Efficacy of a <italic toggle="yes">Campylobacter jejuni</italic> Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-2110.1128/mSphere.00101-192379-5042https://doaj.org/article/e799a4b22d0c4f43842f64674b689c7b2019-06-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mSphere.00101-19https://doaj.org/toc/2379-5042ABSTRACT Campylobacter jejuni is among the most common causes of diarrheal disease worldwide and efforts to develop protective measures against the pathogen are ongoing. One of the few defined virulence factors targeted for vaccine development is the capsule polysaccharide (CPS). We have developed a capsule conjugate vaccine against C. jejuni strain 81-176 (CPS-CRM) that is immunogenic in mice and nonhuman primates (NHPs) but only moderately immunogenic in humans when delivered alone or with aluminum hydroxide. To enhance immunogenicity, two novel liposome-based adjuvant systems, the Army Liposome Formulation (ALF), containing synthetic monophosphoryl lipid A, and ALF plus QS-21 (ALFQ), were evaluated with CPS-CRM in this study. In mice, ALF and ALFQ induced similar amounts of CPS-specific IgG that was significantly higher than levels induced by CPS-CRM alone. Qualitative differences in antibody responses were observed where CPS-CRM alone induced Th2-biased IgG1, whereas ALF and ALFQ enhanced Th1-mediated anti-CPS IgG2b and IgG2c and generated functional bactericidal antibody titers. CPS-CRM + ALFQ was superior to vaccine alone or CPS-CRM + ALF in augmenting antigen-specific Th1, Th2, and Th17 cytokine responses and a significantly higher proportion of CD4+ IFN-γ+ IL-2+ TNF-α+ and CD4+ IL-4+ IL-10+ T cells. ALFQ also significantly enhanced anti-CPS responses in NHPs when delivered with CPS-CRM compared to alum- or ALF-adjuvanted groups and showed the highest protective efficacy against diarrhea following orogastric challenge with C. jejuni. This study provides evidence that the ALF adjuvants may provide enhanced immunogenicity of this and other novel C. jejuni capsule conjugate vaccines in humans. IMPORTANCE Campylobacter jejuni is a leading cause of diarrheal disease worldwide, and currently no preventative interventions are available. C. jejuni is an invasive mucosal pathogen that has a variety of polysaccharide structures on its surface, including a capsule. In phase 1 studies, a C. jejuni capsule conjugate vaccine was safe but poorly immunogenic when delivered alone or with aluminum hydroxide. Here, we report enhanced immunogenicity of the conjugate vaccine delivered with liposome adjuvants containing monophosphoryl lipid A without or with QS-21, known as ALF and ALFQ, respectively, in preclinical studies. Both liposome adjuvants significantly enhanced immunity in mice and nonhuman primates and improved protective efficacy of the vaccine compared to alum in a nonhuman primate C. jejuni diarrhea model, providing promising evidence that these potent adjuvant formulations may enhance immunogenicity in upcoming human studies with this C. jejuni conjugate and other malaria and HIV vaccine platforms.Amritha RamakrishnanNina M. SchumackChristina L. GariepyHeather EgglestonGladys NunezNereyda EspinozaMonica NietoRosa CastilloJesus RojasAndrea J. McCoyZoltan BeckGary R. MatyasCarl R. AlvingPatricia GuerryFrédéric PolyRenee M. LairdAmerican Society for MicrobiologyarticlecampylobacterCampylobacter jejuniadjuvantsconjugateliposomesvaccinesMicrobiologyQR1-502ENmSphere, Vol 4, Iss 3 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
campylobacter Campylobacter jejuni adjuvants conjugate liposomes vaccines Microbiology QR1-502 |
| spellingShingle |
campylobacter Campylobacter jejuni adjuvants conjugate liposomes vaccines Microbiology QR1-502 Amritha Ramakrishnan Nina M. Schumack Christina L. Gariepy Heather Eggleston Gladys Nunez Nereyda Espinoza Monica Nieto Rosa Castillo Jesus Rojas Andrea J. McCoy Zoltan Beck Gary R. Matyas Carl R. Alving Patricia Guerry Frédéric Poly Renee M. Laird Enhanced Immunogenicity and Protective Efficacy of a <italic toggle="yes">Campylobacter jejuni</italic> Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21 |
| description |
ABSTRACT Campylobacter jejuni is among the most common causes of diarrheal disease worldwide and efforts to develop protective measures against the pathogen are ongoing. One of the few defined virulence factors targeted for vaccine development is the capsule polysaccharide (CPS). We have developed a capsule conjugate vaccine against C. jejuni strain 81-176 (CPS-CRM) that is immunogenic in mice and nonhuman primates (NHPs) but only moderately immunogenic in humans when delivered alone or with aluminum hydroxide. To enhance immunogenicity, two novel liposome-based adjuvant systems, the Army Liposome Formulation (ALF), containing synthetic monophosphoryl lipid A, and ALF plus QS-21 (ALFQ), were evaluated with CPS-CRM in this study. In mice, ALF and ALFQ induced similar amounts of CPS-specific IgG that was significantly higher than levels induced by CPS-CRM alone. Qualitative differences in antibody responses were observed where CPS-CRM alone induced Th2-biased IgG1, whereas ALF and ALFQ enhanced Th1-mediated anti-CPS IgG2b and IgG2c and generated functional bactericidal antibody titers. CPS-CRM + ALFQ was superior to vaccine alone or CPS-CRM + ALF in augmenting antigen-specific Th1, Th2, and Th17 cytokine responses and a significantly higher proportion of CD4+ IFN-γ+ IL-2+ TNF-α+ and CD4+ IL-4+ IL-10+ T cells. ALFQ also significantly enhanced anti-CPS responses in NHPs when delivered with CPS-CRM compared to alum- or ALF-adjuvanted groups and showed the highest protective efficacy against diarrhea following orogastric challenge with C. jejuni. This study provides evidence that the ALF adjuvants may provide enhanced immunogenicity of this and other novel C. jejuni capsule conjugate vaccines in humans. IMPORTANCE Campylobacter jejuni is a leading cause of diarrheal disease worldwide, and currently no preventative interventions are available. C. jejuni is an invasive mucosal pathogen that has a variety of polysaccharide structures on its surface, including a capsule. In phase 1 studies, a C. jejuni capsule conjugate vaccine was safe but poorly immunogenic when delivered alone or with aluminum hydroxide. Here, we report enhanced immunogenicity of the conjugate vaccine delivered with liposome adjuvants containing monophosphoryl lipid A without or with QS-21, known as ALF and ALFQ, respectively, in preclinical studies. Both liposome adjuvants significantly enhanced immunity in mice and nonhuman primates and improved protective efficacy of the vaccine compared to alum in a nonhuman primate C. jejuni diarrhea model, providing promising evidence that these potent adjuvant formulations may enhance immunogenicity in upcoming human studies with this C. jejuni conjugate and other malaria and HIV vaccine platforms. |
| format |
article |
| author |
Amritha Ramakrishnan Nina M. Schumack Christina L. Gariepy Heather Eggleston Gladys Nunez Nereyda Espinoza Monica Nieto Rosa Castillo Jesus Rojas Andrea J. McCoy Zoltan Beck Gary R. Matyas Carl R. Alving Patricia Guerry Frédéric Poly Renee M. Laird |
| author_facet |
Amritha Ramakrishnan Nina M. Schumack Christina L. Gariepy Heather Eggleston Gladys Nunez Nereyda Espinoza Monica Nieto Rosa Castillo Jesus Rojas Andrea J. McCoy Zoltan Beck Gary R. Matyas Carl R. Alving Patricia Guerry Frédéric Poly Renee M. Laird |
| author_sort |
Amritha Ramakrishnan |
| title |
Enhanced Immunogenicity and Protective Efficacy of a <italic toggle="yes">Campylobacter jejuni</italic> Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21 |
| title_short |
Enhanced Immunogenicity and Protective Efficacy of a <italic toggle="yes">Campylobacter jejuni</italic> Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21 |
| title_full |
Enhanced Immunogenicity and Protective Efficacy of a <italic toggle="yes">Campylobacter jejuni</italic> Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21 |
| title_fullStr |
Enhanced Immunogenicity and Protective Efficacy of a <italic toggle="yes">Campylobacter jejuni</italic> Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21 |
| title_full_unstemmed |
Enhanced Immunogenicity and Protective Efficacy of a <italic toggle="yes">Campylobacter jejuni</italic> Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21 |
| title_sort |
enhanced immunogenicity and protective efficacy of a <italic toggle="yes">campylobacter jejuni</italic> conjugate vaccine coadministered with liposomes containing monophosphoryl lipid a and qs-21 |
| publisher |
American Society for Microbiology |
| publishDate |
2019 |
| url |
https://doaj.org/article/e799a4b22d0c4f43842f64674b689c7b |
| work_keys_str_mv |
AT amritharamakrishnan enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT ninamschumack enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT christinalgariepy enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT heathereggleston enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT gladysnunez enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT nereydaespinoza enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT monicanieto enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT rosacastillo enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT jesusrojas enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT andreajmccoy enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT zoltanbeck enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT garyrmatyas enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT carlralving enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT patriciaguerry enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT fredericpoly enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 AT reneemlaird enhancedimmunogenicityandprotectiveefficacyofaitalictoggleyescampylobacterjejuniitalicconjugatevaccinecoadministeredwithliposomescontainingmonophosphoryllipidaandqs21 |
| _version_ |
1718428042563420160 |